MCID: LCL006
MIFTS: 65

Localized Scleroderma

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma 12 54 60 38 15 74
Morphea 12 54 56 74
Localized Fibrosing Scleroderma 54 60
Scleroderma, Circumscribed or Localized 12
Circumscribed Scleroderma 12
Scleroderma, Localized 54
Localised Morphoea 12
Localized Morphea 12

Characteristics:

Orphanet epidemiological data:

60
localized scleroderma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 60  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8472
KEGG 38 H01493
ICD9CM 36 701.0
MeSH 45 D012594
NCIt 51 C72069
SNOMED-CT 69 90424004
ICD10 34 L94.0
MESH via Orphanet 46 D012594
ICD10 via Orphanet 35 L94.0
UMLS via Orphanet 75 C0036420
Orphanet 60 ORPHA90289

Summaries for Localized Scleroderma

NIH Rare Diseases : 54 Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, localized scleroderma is serious and disabling. There are two generally recognized types of localized scleroderma: morphea and linear.  

MalaCards based summary : Localized Scleroderma, also known as morphea, is related to fasciitis and keloids, and has symptoms including pruritus and exanthema. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Lidocaine and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and breast, and related phenotypes are hyperpigmentation of the skin and hypopigmentation of the skin

Wikipedia : 77 Morphea, is a form of scleroderma that involves isolated patches of hardened skin on the face, hands,... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
# Related Disease Score Top Affiliating Genes
1 fasciitis 30.1 BMP6 IL6 TNF
2 keloids 30.1 MMP1 SMAD3 TGFB1
3 polyarteritis nodosa 29.7 IL6 SELE SMAD3
4 central nervous system vasculitis 29.6 IL6 TNF
5 vasculitis 29.3 SELE TNF VCAM1
6 arthritis 29.1 IL6 MMP1 MMP13 TGFB1 TNF
7 osteoarthritis 28.8 IL6 MMP1 MMP13 TGFB1 TNF
8 systemic lupus erythematosus 28.6 CXCL10 IL6 SELE TGFB1 TNF VCAM1
9 rheumatoid arthritis 28.1 IL6 MMP1 MMP13 SELE TGFB1 TNF
10 systemic scleroderma 12.2
11 morpheaform basal cell carcinoma 11.6
12 facial hemiatrophy 11.5
13 hemifacial atrophy, progressive 11.5
14 linear scleroderma 11.5
15 atrophoderma of pierini and pasini 11.2
16 reynolds syndrome 10.4
17 fibromatosis, gingival, 1 10.4 MMP1 TGFB1
18 scleroderma, familial progressive 10.4
19 periodontitis, chronic 10.3 IL6 MMP1
20 cholecystolithiasis 10.3 BMP6 TGFB1
21 diabetic foot ulcers 10.3 IL6 TGFB1
22 tuberculoid leprosy 10.3 BMP6 TGFB1
23 kashin-beck disease 10.2 MMP1 TNF
24 gingival disease 10.2 IL6 MMP1 TGFB1
25 dupuytren contracture 10.2 BMP6 DCN TGFB1
26 scorpion envenomation 10.2 IL6 TNF
27 crouzon syndrome 10.2 BMP6 DCN TGFB1
28 leukomalacia 10.2 IL6 TNF
29 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
30 autoimmune myocarditis 10.2 IL6 TNF
31 hypertrophic scars 10.2 BMP6 SMAD3 TGFB1
32 streptococcal toxic-shock syndrome 10.2 IL6 TNF
33 juvenile ankylosing spondylitis 10.2 IL6 TNF
34 anthracosis 10.2 BMP6 TNF
35 cardiogenic shock 10.2 IL6 TNF
36 peyronie's disease 10.2 DCN SMAD3 TGFB1
37 clonorchiasis 10.2 TGFB1 TNF
38 nephrogenic systemic fibrosis 10.2 DCN SMAD3 TGFB1
39 null-cell leukemia 10.2 IL6 TNF
40 retinitis pigmentosa 55 10.2 IL6 TNF
41 renal fibrosis 10.2 BMP6 SMAD3 TGFB1
42 glossitis 10.2 IL6 TNF
43 degos 'en cocarde' erythrokeratoderma 10.1
44 tendinosis 10.1 CXCL10 DCN MMP1
45 acute vascular insufficiency of intestine 10.1 IL6 TNF
46 basal cell carcinoma 1 10.1
47 basal cell carcinoma 10.1
48 psoriasis 10.1
49 scleritis 10.1 SELE TNF
50 osteonecrosis of the jaw 10.1 DEFB1 TGFB1

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

60 33 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperpigmentation of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0000953
2 hypopigmentation of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0001010
3 stiff skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0030053
4 cigarette-paper scars 60 33 hallmark (90%) Very frequent (99-80%) HP:0001073
5 skeletal muscle atrophy 60 33 frequent (33%) Frequent (79-30%) HP:0003202
6 arthralgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002829
7 lipoatrophy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100578
8 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
9 split hand 60 33 occasional (7.5%) Occasional (29-5%) HP:0001171
10 hemiatrophy of upper limb 60 33 occasional (7.5%) Occasional (29-5%) HP:0100558
11 flexion contracture of toe 60 33 occasional (7.5%) Occasional (29-5%) HP:0005830
12 scarring alopecia of scalp 60 33 occasional (7.5%) Occasional (29-5%) HP:0004552
13 hemiatrophy of lower limb 60 33 occasional (7.5%) Occasional (29-5%) HP:0100557
14 flexion contracture 60 Occasional (29-5%)
15 hemiatrophy 60 Occasional (29-5%)
16 dermal atrophy 60 Very frequent (99-80%)

UMLS symptoms related to Localized Scleroderma:


pruritus, exanthema

MGI Mouse Phenotypes related to Localized Scleroderma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CXCL10 DCN IL6 MMP13 SELE SMAD3
2 growth/size/body region MP:0005378 10.11 BMP6 DCN IL6 MMP13 SELE SMAD3
3 cardiovascular system MP:0005385 10.1 CXCL10 IL6 MMP13 SELE SMAD3 TGFB1
4 homeostasis/metabolism MP:0005376 10.1 CXCL10 DCN IL6 MMP1 MMP13 SELE
5 hematopoietic system MP:0005397 10.03 CXCL10 DCN IL6 SELE SMAD3 TGFB1
6 immune system MP:0005387 10.02 CXCL10 DCN IL6 MMP1 SELE SMAD3
7 integument MP:0010771 9.87 DCN IL6 MMP13 SELE SMAD3 TGFB1
8 neoplasm MP:0002006 9.73 DCN IL6 MMP1 SMAD3 TGFB1 TNF
9 reproductive system MP:0005389 9.7 BMP6 DCN IL6 SMAD3 TGFB1 TNF
10 skeleton MP:0005390 9.5 BMP6 DCN IL6 MMP13 SMAD3 TGFB1
11 vision/eye MP:0005391 9.1 DCN IL6 SELE SMAD3 TGFB1 TNF

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
2 Vaccines Phase 4
3 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
6 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
7 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
8 Anesthetics, Local Phase 4,Phase 2,Phase 3
9 Sodium Channel Blockers Phase 4,Phase 2,Phase 3
10 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3
11
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
12
Sodium Citrate Approved, Investigational Phase 3 68-04-2
13
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
14
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
17
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
18
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
19
Domperidone Approved, Investigational, Vet_approved Phase 3,Not Applicable 57808-66-9 3151
20
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
21
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
22
Macitentan Approved Phase 2, Phase 3 441798-33-0
23
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
24
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
25 Antirheumatic Agents Phase 3,Phase 2,Phase 1
26 Adjuvants, Immunologic Phase 3
27 interferons Phase 3,Phase 1
28 Interferon Inducers Phase 3
29 Phosphodiesterase Inhibitors Phase 3,Phase 2
30 Sildenafil Citrate Phase 3,Not Applicable 171599-83-0
31 Citrate Phase 3
32 Vasodilator Agents Phase 3,Phase 2
33 Phosphodiesterase 5 Inhibitors Phase 3
34 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Not Applicable
35 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
36 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
37 Alkylating Agents Phase 3,Phase 2,Phase 1
38 Anticoagulants Phase 3,Phase 1
39 Chelating Agents Phase 3
40 Calcium, Dietary Phase 3,Phase 2,Phase 1,Early Phase 1
41 Neurotransmitter Agents Phase 3
42 Botulinum Toxins, Type A Phase 3
43 Acetylcholine Release Inhibitors Phase 3
44 Neuromuscular Agents Phase 3
45 abobotulinumtoxinA Phase 3
46 insulin Phase 3
47 Cholinergic Agents Phase 3
48 Botulinum Toxins Phase 3
49 Insulin, Globin Zinc Phase 3
50 Antihypertensive Agents Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases Recruiting NCT03388255 Phase 4 Polydeoxyribonucleotides
3 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
4 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
5 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
6 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
7 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
8 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
9 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
10 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
11 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
12 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
13 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
14 CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Recruiting NCT03726398 Phase 2, Phase 3 Opsumit 10 Mg Tablet
15 Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3 imiquimod 5% cream (Aldara)
16 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Unknown status NCT00936546 Phase 2 Rituximab
17 Efficacy and Safety of Imatinib in Scleroderma Completed NCT00479934 Phase 2 imatinib mesylate
18 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Completed NCT00129428 Phase 1, Phase 2
19 Effect of Bosentan in Scleroderma Renal Crisis Completed NCT01241383 Phase 2 Bosentan
20 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
21 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis Completed NCT00764309 Phase 1, Phase 2 dasatinib
22 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed NCT00442611 Phase 1, Phase 2 Abatacept;Placebo
23 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Completed NCT00278525 Phase 2 standard of care
24 IL1-TRAP, Rilonacept, in Systemic Sclerosis Completed NCT01538719 Phase 1, Phase 2 Rilonacept
25 Oral Type I Collagen for Relieving Scleroderma Completed NCT00005675 Phase 2 Oral bovine type I collagen;Placebo
26 Riociguat in Scleroderma Associated Digital Ulcers Completed NCT02915835 Phase 2 Riociguat;Placebo
27 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
28 Zibotentan Better Renal Scleroderma Outcome Study Completed NCT02047708 Phase 2 Zibotentan
29 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
30 Psychological Treatments for Scleroderma Completed NCT00007267 Phase 2
31 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo
32 A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma Recruiting NCT03740724 Phase 1, Phase 2 veledimex
33 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Recruiting NCT03351114 Phase 2 Crisaborole
34 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
35 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Recruiting NCT02213705 Phase 1, Phase 2
36 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Recruiting NCT03221257 Phase 2 Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
37 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
38 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Active, not recruiting NCT02370784 Phase 2 atorvastatin;Placebo
39 Study to Assess Sarilumab in Halting Progression of Morphea Not yet recruiting NCT03679845 Phase 1, Phase 2 Sarilumab
40 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
41 Placebo Controlled Trial of Bosentan in Scleroderma Patients Terminated NCT00377455 Phase 2 Bosentan;Placebo
42 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
43 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1 MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546
44 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Completed NCT02426229 Phase 1 dabigatran etexilate
45 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1 Fludarabine;Cyclophosphamide;Thymoglobulin
46 Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1 Clobetasol;Calcipotriene;Tacrolimus
47 Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Unknown status NCT02002897 Not Applicable
48 Genetic Variants in Linear Localized Scleroderma Unknown status NCT02222038 Not Applicable
49 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Unknown status NCT01799174 Not Applicable
50 Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Unknown status NCT01553890 Not Applicable

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

MalaCards organs/tissues related to Localized Scleroderma:

42
Skin, Lung, Breast, Bone, Prostate, Thyroid, T Cells

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 1046)
# Title Authors Year
1
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin. ( 29863777 )
2019
2
Lichen Sclerosus on the Sites of Striae Distensae and a Surgical Scar in a Patient with Coexistent Morphea. ( 31032793 )
2019
3
Detecting and quantifying activity/inflammation in localized scleroderma with thermal imaging. ( 30030915 )
2019
4
Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. ( 30315656 )
2019
5
Comparison of 2-D shear wave elastography with clinical score in localized scleroderma: A new method to increase the diagnostic accuracy. ( 30506714 )
2019
6
Identifying the Signature Immune Phenotypes Present in Pediatric Localized Scleroderma. ( 30616925 )
2019
7
An extended high-frequency ultrasound protocol for assessing and quantifying of inflammation and fibrosis in localized scleroderma. ( 30638285 )
2019
8
The identification of CCL18 as biomarker of disease activity in localized scleroderma. ( 31006523 )
2019
9
Juvenile localized scleroderma: can we modify treatment strategies based on predictors of relapse? ( 31025742 )
2019
10
Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphea by severity and identify clinically significant change. ( 31049928 )
2019
11
Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. ( 30352282 )
2019
12
Facial solitary morphea profunda presenting with painful trigeminal neuropathy: A case report. ( 30213201 )
2019
13
Postirradiation Morphea in Patients With Breast Cancer: Possible Association With Other Autoimmune Diseases. ( 30389122 )
2019
14
Nodular morphea in a patient with Steinert disease. ( 28895373 )
2019
15
Inflammatory morphea presenting as a hemifacial acquired port-wine stain. ( 29449213 )
2019
16
Generalized morphea in the setting of pembrolizumab. ( 29931792 )
2019
17
Lymphatic Obstruction as a Rare Complication of Morphea and Response to Intralesional Steroid. ( 31057274 )
2019
18
Morphea secondary to interferon beta1b injection: a case and review of the literature. ( 31046913 )
2019
19
Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort. ( 31005342 )
2019
20
Linear morphea overlying site of previous lichen aureus in a pediatric patient. ( 30994203 )
2019
21
Hydroxychloroquine combined with superficial X-ray-A new therapeutic method in the treatment of morphea profunda. ( 30964567 )
2019
22
Cryolipolysis-induced morphea. ( 30963082 )
2019
23
Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. ( 30838436 )
2019
24
Radiation-induced morphea: association with autoimmune comorbidities, severity, and response to therapy. ( 30797843 )
2019
25
Isomorphic Morphea in a Girl Motorcyclist. ( 30795836 )
2019
26
Dermoscopy of Morphea. ( 30775314 )
2019
27
Radiation-induced morphea: autoimmunity as a risk factor. ( 30774102 )
2019
28
A case of linear morphea involving the oral cavity. ( 30733981 )
2019
29
An evaluation of long-term outcomes and recurrence rates in patients with morphea. ( 30710337 )
2019
30
Cutaneous lymphoid hyperplasia arising in pre-existing morphea plaques treated with methotrexate. ( 30705931 )
2019
31
Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. ( 30703458 )
2019
32
Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: A case report and review of the published works. ( 30701571 )
2019
33
A Case of Pansclerotic Morphea Treated With Tocilizumab. ( 30649148 )
2019
34
Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib. ( 29760872 )
2018
35
Granuloma Annulare and Morphea: Correlation with Borrelia burgdorferi Infections and Chlamydia-related Bacteria. ( 29110020 )
2018
36
Comorbidity of localized scleroderma and primary biliary cholangitis. ( 30395408 )
2018
37
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
38
Case of generalized morphea with the manifestation of diffuse systemic cutaneous sclerosis without sclerodactyly. ( 29215147 )
2018
39
Fluoroscopy-induced chronic radiation dermatitis masquerading as morphea: A diagnostic pitfall. ( 30004062 )
2018
40
Localized scleroderma causing enophthalmos: A rare entity. ( 30355873 )
2018
41
Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. ( 29892660 )
2018
42
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. ( 29984277 )
2018
43
Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: A comparative study of 27 cases. ( 28865864 )
2018
44
Granulomatous fasciitis followed by morphea profunda: Is granulomatous fasciitis part of a spectrum of deep morphea? A case report and review of the literature. ( 30147873 )
2018
45
Atypical generalized morphea-like scleroderma occurring in a patient exposed to organic solvents and having chronic hepatitis C virus infection. ( 29451196 )
2018
46
Morphea «En Coup De Sabre» at the Site of Healed Herpes Zoster Ophthalmicus. ( 30201544 )
2018
47
Morphea and Extragenital Lichen Sclerosus et Atrophicus After Influenza Vaccination. ( 29025691 )
2018
48
A case of radiation-induced bullous morphea/lichen sclerosus overlap in a breast cancer patient. ( 29872368 )
2018
49
Concomitant morphea and lichen sclerosus et atrophicus in the same plaque at the site of intramuscular drug injection: an interesting case presentation. ( 29945269 )
2018
50
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. ( 30013378 )
2018

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 CXCL10 IL6 MMP1 TGFB1 TNF VCAM1
2
Show member pathways
13.18 BMP6 CXCL10 IL6 SMAD3 TGFB1 TNF
3
Show member pathways
12.98 CXCL10 IL6 SMAD3 TGFB1 TNF
4
Show member pathways
12.64 DCN MMP1 MMP13 TGFB1 VCAM1
5
Show member pathways
12.61 BMP6 IL6 TGFB1 TNF
6
Show member pathways
12.51 IL6 SMAD3 TGFB1 TNF
7 12.25 IL6 SMAD3 TGFB1 TNF VCAM1
8
Show member pathways
12.23 CXCL10 IL6 MMP1 MMP13 TNF
9
Show member pathways
12.18 BMP6 IL6 TGFB1 TNF
10
Show member pathways
12.15 MMP1 SELE TGFB1
11 12.15 IL6 TGFB1 TNF
12
Show member pathways
12.14 IL6 TGFB1 TNF
13
Show member pathways
12.11 CXCL10 IL6 TNF
14 12.09 IL6 SMAD3 TGFB1
15 12.07 BMP6 SMAD3 TGFB1
16 12.07 IL6 MMP1 SMAD3 TGFB1 TNF
17
Show member pathways
12.05 IL6 SMAD3 TGFB1
18 12.02 SELE TNF VCAM1
19
Show member pathways
12.01 IL6 SMAD3 TGFB1
20 11.99 IL6 TGFB1 VCAM1
21 11.99 MMP1 SMAD3 TGFB1
22
Show member pathways
11.99 BMP6 IL6 SMAD3 TGFB1
23 11.99 IL6 SMAD3 TGFB1 TNF
24 11.98 BMP6 SMAD3 TGFB1
25
Show member pathways
11.96 IL6 SMAD3 TGFB1 TNF
26 11.92 CXCL10 IL6 TGFB1 TNF
27 11.87 IL6 SMAD3 TGFB1
28
Show member pathways
11.83 MMP1 MMP13 TNF
29 11.82 IL6 TGFB1 TNF
30 11.82 IL6 MMP1 TGFB1 TNF VCAM1
31
Show member pathways
11.79 IL6 SMAD3 TGFB1
32 11.78 IL6 MMP1 TGFB1 TNF
33 11.76 CXCL10 IL6 SELE TNF VCAM1
34 11.73 IL6 MMP1 SELE
35 11.68 IL6 TGFB1 TNF
36 11.63 BMP6 SMAD3 TGFB1
37 11.63 CXCL10 IL6 TGFB1 TNF
38 11.63 BMP6 DCN SMAD3 TGFB1 TNF
39 11.62 BMP6 MMP13 TGFB1
40 11.59 IL6 TGFB1 TNF
41 11.55 SMAD3 TGFB1 TNF
42 11.47 CXCL10 IL6 TNF
43 11.44 IL6 MMP1 SMAD3 TGFB1
44 11.41 IL6 SMAD3 TNF
45
Show member pathways
11.35 IL6 MMP1 SELE TNF VCAM1
46 11.28 DCN IL6 MMP1
47 11.27 IL6 SELE TNF VCAM1
48 11.2 IL6 TGFB1 TNF
49 11.13 BMP6 CXCL10 IL6 TNF
50 11.1 IL6 SELE SMAD3 TGFB1 TNF VCAM1

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BMP6 CXCL10 DCN DEFB1 IL6 MMP1
2 extracellular matrix GO:0031012 9.46 DCN MMP1 MMP13 TGFB1
3 Golgi lumen GO:0005796 9.43 DCN DEFB1 TGFB1
4 extracellular space GO:0005615 9.32 BMP6 CXCL10 DCN DEFB1 IL6 MMP13

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 IL6 SMAD3 TGFB1 TNF
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 BMP6 CXCL10 DCN IL6 SMAD3 TGFB1
3 regulation of signaling receptor activity GO:0010469 9.93 BMP6 CXCL10 IL6 TGFB1 TNF
4 aging GO:0007568 9.87 DCN TGFB1 VCAM1
5 regulation of cell proliferation GO:0042127 9.87 CXCL10 TGFB1 TNF
6 response to hypoxia GO:0001666 9.87 SMAD3 TGFB1 VCAM1
7 leukocyte migration GO:0050900 9.87 MMP1 SELE TGFB1 TNF
8 cellular response to lipopolysaccharide GO:0071222 9.86 CXCL10 IL6 TNF
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 IL6 TGFB1 TNF
10 defense response GO:0006952 9.83 CXCL10 DEFB1 TNF
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.82 IL6 SMAD3 TNF
12 defense response to Gram-positive bacterium GO:0050830 9.8 DEFB1 IL6 TNF
13 wound healing GO:0042060 9.8 DCN SMAD3 TGFB1
14 response to lipopolysaccharide GO:0032496 9.8 CXCL10 DCN SELE VCAM1
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 IL6 TGFB1 TNF
16 response to glucocorticoid GO:0051384 9.77 BMP6 IL6 TNF
17 SMAD protein signal transduction GO:0060395 9.76 BMP6 SMAD3 TGFB1
18 immune response GO:0006955 9.73 BMP6 CXCL10 DEFB1 IL6 SMAD3 TNF
19 endochondral ossification GO:0001958 9.7 BMP6 MMP13
20 extrinsic apoptotic signaling pathway GO:0097191 9.7 SMAD3 TGFB1 TNF
21 negative regulation of neurogenesis GO:0050768 9.69 IL6 TNF
22 positive regulation of protein complex assembly GO:0031334 9.68 TGFB1 TNF
23 cell-cell junction organization GO:0045216 9.68 SMAD3 TGFB1
24 calcium-mediated signaling using intracellular calcium source GO:0035584 9.68 DEFB1 VCAM1
25 positive regulation of chondrocyte differentiation GO:0032332 9.67 BMP6 SMAD3
26 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.67 SMAD3 TGFB1
27 positive regulation of chemokine production GO:0032722 9.66 IL6 TNF
28 response to vitamin D GO:0033280 9.66 CXCL10 TGFB1
29 positive regulation of glial cell proliferation GO:0060252 9.65 IL6 TNF
30 negative regulation of mitotic cell cycle GO:0045930 9.65 SMAD3 TGFB1 TNF
31 lens fiber cell differentiation GO:0070306 9.64 SMAD3 TGFB1
32 positive regulation of SMAD protein signal transduction GO:0060391 9.63 BMP6 TGFB1
33 positive regulation of bone mineralization GO:0030501 9.63 BMP6 SMAD3 TGFB1
34 inflammatory response GO:0006954 9.63 BMP6 CXCL10 IL6 SELE TGFB1 TNF
35 negative regulation of lipid storage GO:0010888 9.62 IL6 TNF
36 SMAD protein complex assembly GO:0007183 9.61 SMAD3 TGFB1
37 positive regulation of neuroinflammatory response GO:0150078 9.59 IL6 TNF
38 positive regulation of extracellular matrix assembly GO:1901203 9.58 SMAD3 TGFB1
39 regulation of binding GO:0051098 9.56 SMAD3 TGFB1
40 regulation of striated muscle tissue development GO:0016202 9.55 SMAD3 TGFB1
41 negative regulation of myoblast differentiation GO:0045662 9.54 CXCL10 TGFB1 TNF
42 positive regulation of mononuclear cell migration GO:0071677 9.51 TGFB1 TNF
43 leukocyte tethering or rolling GO:0050901 9.5 SELE TNF VCAM1
44 evasion or tolerance of host defenses by virus GO:0019049 9.43 SMAD3 TGFB1
45 negative regulation of fat cell differentiation GO:0045599 9.26 IL6 SMAD3 TGFB1 TNF
46 cytokine-mediated signaling pathway GO:0019221 9.1 CXCL10 IL6 MMP1 TGFB1 TNF VCAM1

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 BMP6 IL6 TGFB1
2 collagen binding GO:0005518 9.33 DCN MMP13 SMAD3
3 transforming growth factor beta receptor binding GO:0005160 9.13 BMP6 SMAD3 TGFB1
4 cytokine activity GO:0005125 9.02 BMP6 CXCL10 IL6 TGFB1 TNF

Sources for Localized Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....